Clinical Trials

Can a Gene Vector Work for Long Term?

Lentiviral vector expresses protein for up to four years in trial.

Drugability of the Suprachoroidal Space

Phase II trial shows Clearside’s CLS-TA safe and effective in noninfectious uveitis.

Argus II in the Real World

Experience with six patients who have had this device implanted.

SPK-RPE65 Gene ‘Augmentation’

This biological agent targets mutations in genes that mediate visual transduction.

AKB-9778 as an Adjunct to Anti-VEGF

A deeper dive into how this Tie-2 activator stabilizes the retinal vasculature.

10 Abstracts Worth a Second Look

A review of compelling presentations in retina from ARVO.

Impact of the OHR-102 IMPACT Data

A closer look at combination therapy and CNV.

Real-life Story of the 'Bionic Eye,' the Argus II

A real-life experience with the only retinal prosthesis approved by the FDA and Health Canada.


Lead investigator provides details on parallel trials of lampalizumab.

Can Anti-VEGF Cause GA in Wet AMD?

A host of trials are trying to answer this question. Here’s what they’ve found so far.

Lessons from Protocol T

What we can take from the study and apply in our clinics.